SEOM guidelines for endometrial cancer
Tóm tắt
Endometrial cancer (EC) is the most common gynaecological tumour in developing countries. Most patients with EC are diagnosed at an early stage with a low risk of relapse and overall survival at 5 years greater than 85%. Nevertheless, there is a subgroup of patients with a very poor prognosis due to the pathological features and molecular characteristics. Until now there has been no consensus regarding adjuvant treatment in EC patients, with many open questions: In which patients is it indicated? Which is the best approach: chemotherapy, radiotherapy or both? What is the right timing? Relevant clinical trials are in progress in order to answer these questions. Unfortunately, the survival of patients with metastatic or recurrent EC is quite short due to the poor responses to standard first-line chemotherapy and the lack of second lines of treatment.
Tài liệu tham khảo
Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300
Ellenson lH, Ronnett BM, Soslow RA et al (2011) Endometrial carcinoma. In: Kurman RJ, Ellenson lH, Ronnett BM (eds) Blaustein's pathology of the female genital tract, 6th edn. Springer, Berlin, pp 393–452
Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104
ASTEC/EN.5 Study Group. Blake P, Swart AM, Orton J et al (2009) Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. lancet 373:137–146
Nout RA, Smit VT, Putter H et al (2010) Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, noninferiority, randomised trial. lancet 375:816–823
Kitchener H, Swart AM, Qian Q et al (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. lancet 373:125–136
Benedetti Panici P, Basile S, Maneschi F et al (2008) Systemic pelvic lymphadenectomy vs no lymphadenectomy in early stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716
Creutzberg C, van Putten Wl, Koper P et al (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomized trial. Lancet 355:1404–1411
Keys HM, Roberts JA, Brunetto Vl et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecolgic Oncology Group study. Gynecol Oncol 92:744–751
Maggi R, Lissoni A, Spina A et al (2006) Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95:266–271
Susumu N, Sagae S, Udagawa y et al (2008) Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 108:226–233
Hogberg T, Signorelli M, de Oliveira CF et al (2010) Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer. Results from two randomized studies. Eur J Cancer 46:2422–2431
Greven K, Winter K, Underhill K et al (2006) Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 103:155–159
Randall ME, Filiaci Vl, Muss H et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 24:36–44
Thigpen JT, Brady MF, Homesley HD et al (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 22:3902–3908
Fleming GF, Brunnetto Vl, Cella D et al (2004) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgastrim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 22:2159–2166
Thigpen JT, Brady MF, Alvarez RD et al (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17:1736–1744